Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "pulmonary hypertension" Clear all
Recruiting No phase listed Observational

Pulmonary Hypertension Biorepository and Registry

NCT04808596
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Not applicable Interventional

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

NCT01039324
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions
Reports, Reports and Notices, Usual care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
8,422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 24, 2026, 6:02 PM EDT
Recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 24, 2026, 6:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Observation of Exercise Parameters in Advanced Heart Failure

NCT01210573
View directory record Official record
Conditions
Advanced Heart Failure
Interventions
adjustment of LVAD or pacemaker
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

NCT00352482
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil (50 mg)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
APD811, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 24, 2026, 6:02 PM EDT
Not listed No phase listed Observational

Glucocorticoids and Pulmonary Hypertension

NCT04499196
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions
GlucoCorticoid
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 24, 2026, 6:02 PM EDT
Recruiting No phase listed Observational

Effect of Fetal Aortic Valvuloplasty on Outcomes

NCT05386173
View directory record Official record
Conditions
Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
Interventions
Fetal aortic balloon dilatation
Procedure
Lead sponsor
Queen Silvia Children's Hospital, Gothenburg, Sweden
Other
Eligibility
23 Weeks to 31 Weeks
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 24, 2026, 6:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Iowa City, Iowa • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Miconazole on Blood Flow

NCT00004575
View directory record Official record
Conditions
Healthy
Interventions
Miconazole, L-NMMA, Bradykinin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 2Phase 3 Interventional

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

NCT00851929
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Jul 24, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

NCT02734953
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Jul 24, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Patients With Pulmonary Arterial Hypertension

NCT01094067
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-050089, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine and Pulmonary Hypertension

NCT01174173
View directory record Official record
Conditions
Angina, Pulmonary Arterial Hypertension
Interventions
Ranolazine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 24, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

NCT04394624
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
SAR408701, ramucirumab, pembrolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Detroit, Michigan • Buffalo, New York • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Not applicable Interventional Results available

Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.

NCT02963597
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
Interventions
AirSense™ 10 AutoSet, Standard Medical Therapy
Device · Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 24, 2026, 6:02 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Not applicable Interventional

NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn

NCT00139217
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
iNO, Non-invasive nitric oxide
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jul 24, 2026, 6:02 PM EDT
Not listed Phase 2 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Long Term Follow Up
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

NCT01117025
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions
Circumferential PV isolation, Circumferential PVI+renal denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jul 24, 2026, 6:02 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Background PAH Therapy
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 24, 2026, 6:02 PM EDT
Completed Not applicable Interventional Results available

Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension

NCT05387889
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Mindfulness Meditation for Pulmonary Hypertension (MMPH)
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Jul 24, 2026, 6:02 PM EDT